BrainStorm price target raised to $10 from $5 at Maxim

Maxim analyst Jason McCarthy raised the firm’s price target on BrainStorm to $10 from $5 and keeps a Buy rating on the shares after the company’s FY22 results. The company should continue to have the cash runway while advancing its lead asset NurOwn through regulatory review for amytrophic lateral sclerosis and with earlier stage programs in multiple sclerosis and Alzheimer’s disease, the analyst tells investors in a research note. The firm is lso adjusting its model with moved timelines to potential approval and commercialization up to 2025 from 2027.